SUBSCRIBE
SUBSCRIBE

Juno Therapeutics

NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
BioForest
Here’s What Juno Therapeutics Really Thinks About Local Rival Adaptive Biotech
May 29, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Editas Medicine, Juno Therapeutics Hammer Out $727 Million CAR T R&D Deal
May 27, 2015
 · 
10 min read
Job Trends
Four Seattle Biotech Firms Looking to Hire Hundreds of New Employees
May 21, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
White-Hot Juno Therapeutics Goes Shopping Again, Shelling Out $81 Million for Stage Cell Therapeutics
May 11, 2015
 · 
7 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
$60 Million Juno Therapeutics Deal Pushes Fate Therapeutics Up 80% in Premarket Trading
May 6, 2015
 · 
7 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
CAR-T Cell Companies Juno Therapeutics, Kite Pharma, and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG Trial News
April 21, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Roaring Juno Therapeutics Ends Quest for New Headquarters and Blueprints Plans to Keep Investors Happy
April 9, 2015
 · 
2 min read
BioForest
Juno Therapeutics CEO, Arch Co-Founder Say Federal Innovation Act Would “Trash The Next Generation” Of Biotechs
March 26, 2015
 · 
1 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Juno Therapeutics Falls as Company Projects Up to $150 Million Cash Burn in First Post-IPO Earnings Report
March 19, 2015
 · 
5 min read
Load More
AWARDS
  • NextGen Class of 2015
JOBS
IN THE PRESS
Deals
Juno Therapeutics Announces Pricing Of Initial Public Offering
December 19, 2014
 · 
1 min read
Drug Development
Juno Therapeutics’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes In Clinical Trials In Patients With B-Cell Cancers
December 9, 2014
 · 
7 min read
Business
Juno Therapeutics Executes License For Phase I CAR T Product Candidate Targeting CD22 For Hematological Malignancies
December 5, 2014
 · 
4 min read
Business
Juno Therapeutics Appoints Jeffrey Bluestone As Scientific Advisor
December 2, 2014
 · 
2 min read
Business
Juno Therapeutics Appoints Maggie Wilderotter To Board Of Directors
November 25, 2014
 · 
2 min read
Drug Development
Juno Therapeutics T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation
November 24, 2014
 · 
3 min read
Drug Development
Juno Therapeutics’s JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA
November 18, 2014
 · 
2 min read
Business
Juno Therapeutics Appoints Hal Barron, M.D. To Board Of Directors
October 1, 2014
 · 
2 min read
Business
MabVax Therapeutics, Inc. Enters Agreements With Memorial Sloan-Kettering Cancer Center And Juno Therapeutics For Development Of Anti-Cancer Therapeutics
September 10, 2014
 · 
3 min read
Business
Fresh From Co-Founding Massively Financed Juno Therapeutics, Arch Venture Partners Banks $400 Million+ To Back New Biotechs
August 27, 2014
 · 
3 min read
Load More